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We agree with de Wildt et al. on the need to take children’s
developmental changes into consideration when assessing
the clinical evidence in order to waive additional studies.
In reviewing the available evidence on the use of proton
pump inhibitors (PPIs) in the treatment of gastroesophageal
reflux disease (GERD) in children, we focused on the age
ranges for which no labeled indication was approved in the
EU [1]. For example, in the case of omeprazole (authorized
for the treatment of GERD in Europe for children ≥
2 years), we searched for scientific literature based on
children younger than 2 years. We found four trials entirely
dedicated to children aged 0–2 years. The remaining two
trials, although not strictly dedicated to that target popula-
tion, also enrolled children between 0 and 2 years.
Our review intended to deal with the general issue of off-
labeluseofdrugsinthepediatricpopulation,toverifywhether
drugs not formally approved for use in a specific population
may nonetheless present sufficient evidence supporting their
(off-label) use. If the 0- to 2-year range is still considered too
largetotakeintoaccounttheimpactofdevelopmentalchanges
on a drug risk/benefit profile, further studies focusing on more
specific age groups are clearly needed. Prior biological
knowledge, or new data, are critical factors in deciding
whether the available evidence is insufficient to guide clinical
practice in a specific population sub-group.
However, we should also use a pragmatic and prioritiz-
ing approach, considering that requiring separate trials for
each patient sub-group—in pediatrics as well as in other
populations—may not be always feasible. For instance, in
the case of the elderly, the combination of different age
strata, co-morbidities, and concomitant use of different
drugs may create an enormous number of potential different
groups. The issue of how to generalize data deriving from a
specific population to a wider population is inevitably to be
considered on a case-by-case basis. Mathematical modeling
may provide a contribution though, again, the applicability
of existing evidence to different patient groups will
continue to carry various degrees of uncertainty.
With regards to who should assess the use of off-label
medicines in children, we agree on the importance of
regulatory agencies in reviewing the available evidence to
support clinical practice and to identify research priorities
(a “to do” list). In the effort to deal with this issue, different
strategies and approaches have been used at the regulatory
level. In Europe, the EMEA Paediatric Committee has
identified the needs in different therapeutic areas where
there should be research and development of medicinal
products for children [2]. In the U.S., the FDA has recently
Eur J Clin Pharmacol (2009) 65:851–852
DOI 10.1007/s00228-009-0677-9
G. Tafuri: H. G. M. Leufkens
Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
PO Box 80 082, 3508 TB Utrecht, The Netherlands
G. Tafuri: F. Trotta (*): G. Traversa
Italian Medicines Agency (AIFA),
via della Sierra Nevada 60,
00144 Rome, Italy
e-mail: f.trotta@aifa.gov.it
H. G. M. Leufkens
Medicines Evaluation Board (MEB),
PO Box 16229, 2500 BE The Hague, The Netherlands
N. Martini
National Academy of Medicine,
Via Martin Piaggio 17/6,
16122 Genova, Italy
L. Sagliocca
Local Health Unit Salerno 1,
via Giovanni Falcone 70,
84014 Nocera Inferiore (SA), Italyreleased specific guidelines allowing drug manufacturers to
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attitude that can be of help in regulating evidence-based
off-label drug use [3].
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